prikaz prve stranice dokumenta Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
  Download
PDF 1.1 MB
Scientific paper - Original scientific paper
Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
Journal of Clinical Medicine, 11 (2022), 22; 6695. https://doi.org/10.3390/jcm11226695
Krpina, Kristina; Mavrinac, Martina; Samaržija, Miroslav; Tolić, Ena; Darapi, Dora; Batičić, Lara

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Krpina, K., Mavrinac, M., Samaržija, M., Tolić, E., Darapi, D. & Batičić, L. (2022). Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection. Journal of Clinical Medicine, 11. (22). doi: 10.3390/jcm11226695

Krpina, Kristina, et al. "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection." Journal of Clinical Medicine, vol. 11, no. 22, 2022. https://doi.org/10.3390/jcm11226695

Krpina, Kristina, Martina Mavrinac, Miroslav Samaržija, Ena Tolić, Dora Darapi and Lara Batičić. "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection." Journal of Clinical Medicine 11, no. 22 (2022). https://doi.org/10.3390/jcm11226695

Krpina, K., et al. (2022) 'Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection', Journal of Clinical Medicine, 11(22). doi: 10.3390/jcm11226695

Krpina K, Mavrinac M, Samaržija M, Tolić E, Darapi D, Batičić L. Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection. Journal of Clinical Medicine [Internet]. 2022 November 11 [cited 2024 November 25];11(22). doi: 10.3390/jcm11226695

K. Krpina, M. Mavrinac, M. Samaržija, E. Tolić, D. Darapi and L. Batičić, "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection", Journal of Clinical Medicine, vol. 11, no. 22, November 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:924366. [Accessed: 25 November 2024]

Metadata
Title (english)Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
AuthorKristina Krpina
AuthorMartina Mavrinac
AuthorMiroslav Samaržija
AuthorEna Tolić
AuthorDora Darapi
AuthorLara Batičić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Introduction: Lung cancer is one of the most diagnosed malignancies with increasing incidence worldwide. Immunotherapy is the main oncological treatment for advanced non-small cell lung cancer (NSCLC), for which the discovery of new efficient biomarkers is crucial. Scientific evidence points to the importance of the Lung Immune Prognostic Index (LIPI), but its predictive significance is unclear. Aim: The aim of this study was to investigate the clinical significance and predictive role of LIPI in patients with advanced NSCLC and PD-L1 mutation who are eligible for immunotherapy in combination with chemotherapy. In addition, to our knowledge, this is the first time that the association between COVID-19 infection and the course and outcome of oncologic treatment of NSCLC has been investigated. Patients and Methods: Patients were divided into four study groups according to strictly defined clinical parameters, therapeutic approach, and COVID-19 infection. LIPI was determined and its predictive power was evaluated in all studied groups, as well as overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). Results: This study confirmed the understudied and uncertain predictive power and clinical relevance of LIPI as a biomarker in patients with advanced NSCLC. Patients infected with COVID-19 had a higher survival rate than uninfected patients despite the therapeutic approach, which may be attributed to their hospitalization and intensive medical management during the pandemic. Conclusions: Findings obtained in this study may help to determine treatment options according to the clinical condition of the patient by using LIPI values as a non-invasive, readily available and economically acceptable predictive biomarker in lung oncology.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Clinical Medicine
Numberingvol. 11, no. 22, 6695
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm11226695
URN:NBNurn:nbn:hr:105:924366
Publication2022-11-11
Document URLhttps://www.mdpi.com/2077-0383/11/22/6695
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-06-12 11:42:11